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RESEARCH ARTICLE
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Abstract
Background
Methamphetamine (MA) is a potent agonist at the trace amine-associated receptor 1
(TAAR1). This study evaluated a common variant (CV) in the human TAAR1 gene, synony-
mous single nucleotide polymorphism (SNP) V288V, to determine the involvement of
TAAR1 in MA dependence.
Methods
Participants (n = 106) with active MA dependence (MA-ACT), in remission from MA depen-
dence (MA-REM), with active polysubstance dependence, in remission from polysubstance
dependence, and with no history of substance dependence completed neuropsychiatric
symptom questionnaires and provided blood samples. In vitro expression and function of
CV and wild type TAAR1 receptors were also measured.
Results
The V288V polymorphism demonstrated a 40% increase in TAAR1 protein expression in
cell culture, but message sequence and protein function were unchanged, suggesting an
increase in translation efficiency. Principal components analysis resolved neuropsychiatric
symptoms into four components, PC1 (depression, anxiety, memory, and fatigue), PC2
(pain), PC3 (drug and alcohol craving), and PC4 (sleep disturbances). Analyses of study
group and TAAR1 genotype revealed a significant interaction for PC3 (craving response) (p
= 0.003). The control group showed no difference in PC3 associated with TAAR1, while
adjusted mean craving for the MA-ACT and MA-REM groups, among those with at least one
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copy of V288V, was estimated to be, respectively, 1.55 (p = 0.036) and 1.77 (p = 0.071)
times the adjusted mean craving for those without the TAAR1 SNP.
Conclusions
Neuroadaptation to chronic MA use may be altered by TAAR1 genotype and result in
increased dopamine signaling and craving in individuals with the V288V genotype.
Introduction
Addiction to methamphetamine (MA) is a costly substance use disorder and is a growing con-
cern, as highlighted by recent media headlines (“Meth, the Forgotten Killer, Is Back. And It’s
Everywhere”; [1], “Meth, Cheaper And Deadlier, Is Surging Back.”, [1]). Recent epidemiologi-
cal surveys have likewise documented a resurgence of MA use [2, 3] and an increase in associ-
ated fatalities [4]. MA is among the 10 most frequently mentioned drugs contributing to
overdose deaths, and from 2011 through 2016, the rate of drug overdose deaths involving MA
more than tripled [4]. Genetic factors contribute to risk for drug-seeking behavior, as well as
to variability in addiction treatment outcomes. Polymorphisms in several genes are associated
with drug dependence [5], including genes encoding opioid receptors (e.g., OPRM1 [6]), phos-
pholipase C beta 1 protein [7], and prodynorphin [8], (see also [9] for review). These gene vari-
ants may function synergistically with polymorphisms associated with comorbid
neuropsychiatric symptoms that are common in addictions, such as anxiety or depression.
Gene variants may also modify vulnerability to relapse and treatment response at specific
stages of addiction. One leading candidate gene, which significantly influences MA use and
response in animal models [10, 11], is the trace amine-associated receptor 1 (TAAR1) gene.
Among the studied disorders in which TAAR1 plays a crucial role, drug addiction, particularly
stimulant addiction, is increasingly under investigation (reviewed in [12]).
In brain, the TAAR1 appears to function as an endogenous rheostat, regulating receptor
activation in neurotransmitter systems, particularly the dopaminergic system [13]. Impor-
tantly, in addition to MA’s direct interactions with the dopaminergic system, MA is a potent
agonist at the TAAR1 [14]. There are approximately 50 synonymous and 50 non-synonymous
single nucleotide polymorphisms (SNPs) in the human TAAR1 (dbSNP database, NCBI), and
function-modifying polymorphisms of the human TAAR1 gene are evident in vitro [15]. In
mice, a non-functional Taar1 allele segregates with high MA use, implying a protective role for
TAAR1 function in the context of MA exposure [16]. TAAR1 has been implicated in human
conditions associated with pathological monoaminergic and immune system function, includ-
ing schizophrenia [17], fibromyalgia [18], migraine [19], and addictions [15, 20–23]. It is not
known, however, whether differences in TAAR1 gene sequences are associated with human
MA addiction. This study evaluated a common variant (CV) in the human TAAR1 gene, a
SNP in a valine (V) codon (rs8192620 on human [GRCh38.p7] chromosome 6 at 132,645,140
bp in hTAAR1), occurring at amino acid position 288 and is designated V288V. The goal was
to determine the involvement of TAAR1 in humans with MA dependence—collectively inves-
tigating TAAR1 genotype-phenotype interactions in MA addiction and recovery.
Materials and methods
Research participants
Participants were recruited from Portland, Oregon (OR) area addiction treatment centers and
the community through word of mouth and via study advertisements posted in clinics,
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websites, and newspapers. Individuals were enrolled into one of five groups: 1) control (CTL)
group (n = 31): adults with no lifetime history of dependence on any substance other than nic-
otine or caffeine; 2) MA-active (MA-ACT) group (n = 13): adults actively using MA and cur-
rently meeting criteria for MA dependence; 3) MA-remission (MA-REM) group (n = 19):
adults in early remission from MA dependence� 1 month and� 6 months; 4) active polysub-
stance dependence (POLY-ACT) group (n = 11): adults actively using and dependent on MA
and at least one other substance (other than caffeine or nicotine); and 5) polysubstance remis-
sion (POLY-REM) group (n = 32): adults in early remission (abstinence� 1 month and� 6
months) from dependence on MA and at least one other substance (other than caffeine or nic-
otine). (Note: Although the currently accepted terminologies are MA use disorder and polysub-
stance use disorder, as per the DSM-5, the diagnostic categories were previously termed MA
dependence and polysubstance dependence, and these terms are used when referring to the
research participants described in this paper). This study was reviewed and approved by the
Veterans Affairs Portland Health Care System and Oregon Health & Science University Insti-
tutional Review Boards. The procedures followed were in accordance with the ethical stan-
dards of these institutional review boards and with the Helsinki Declaration, as revised in
2004. Written informed consent was received from participants prior to inclusion in the study.
General exclusion criteria included: 1) history of major medical illness (by subject self-
report during the structured interview) or current use of medications that are likely to be asso-
ciated with serious neurological or immune dysfunction [e.g., stroke, traumatic brain injury,
human immunodeficiency virus (HIV) infection, primary psychotic disorder or active psycho-
sis, immunosuppressants, antivirals, benzodiazepines, opiates, stimulants, antipsychotics, anti-
cholinergics, antiparkinson agents], 2) visible intoxication or impaired capacity to understand
study risks and benefits or otherwise provide informed consent, and 3) based on the Diagnos-
tic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) [24] with confirma-
tion by the Mini International Neuropsychiatric Interview questionnaire (MINI) [25], meets
criteria for past or current manic episode, schizophrenia, schizoaffective disorder, or other
psychotic disorder. (Note that a history of temporary substance-induced psychosis was accept-
able for participants in the substance use groups, as long as they did not currently meet criteria
for a psychotic disorder, and they did not meet criteria for a psychotic disorder prior to active
substance abuse).
Additional exclusion criteria for the control group included: 1) meets criteria for lifetime
history of dependence on any substance (other than nicotine or caffeine dependence) based on
the DSM-IV [24] with confirmation by the MINI [25], 2) heavy alcohol use as defined by the
National Institute on Alcohol Abuse and Alcoholism (women: average alcohol use� 7 stan-
dard drinks weekly for� 1 year; men: average alcohol use� 14 standard drinks weekly
for� 1 year [26]), 3) use of marijuana > 2 times per month, 4) regular use of other addictive
substances, 5) on the day of the study visits, tests positive on a urine drug analysis for any
addictive drugs, including alcohol and marijuana, and 6) education beyond an associate’s
degree.
Inclusion criteria for the MA dependent groups included: 1) DSM-IV criteria [24] (with
confirmation by the MINI [25]) for MA dependence, 2) MA use > 2 days per week for > 1
year, and 3) no dependence [DSM-IV criteria [24] with confirmation by the MINI [25]) on
other substances. Inclusion criteria for the polysubstance-dependent groups included: 1)
DSM-IV criteria (with confirmation by the MINI [25]) for dependence on MA and at least
one other substance (other than caffeine or nicotine), and 2) MA use> 2 days per week
for> 1 year. Inclusion criteria for the active groups included: 1) meets DSM-IV criteria [24]
for dependence on MA with confirmation by the MINI [25], 2) average MA use of� 2 days
per week for� 1 year, and 3) last use of MA was� 2 weeks ago. Inclusion criteria for the
Trace amine-associated receptor gene polymorphism and drug craving
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remission groups included: 1) all criteria for the active groups, except last use of MA and other
substances (other than caffeine and nicotine) was� 1 and� 6 months ago, and 2) on the day
of the study visit, does not test positive for any addictive drugs, including alcohol and
marijuana.
Procedures
Participants completed a structured clinical interview (MINI), urine drug screen [Uscreen 6
Panel Drug Test Cups (RapidDetectINC, Poteau, OK, USA)], HCV and HIV antibody screen,
neuropsychological tests and provided a blood sample. Neuropsychological measures included
the Patient Health Questionnaire (PHQ-9) to assess depressive symptoms [27], Generalized
Anxiety Disorder 7-item scale (GAD-7) [28], Prospective and Retrospective Memory Ques-
tionnaire (PRMQ), a 16-item measure which records the frequency with which subjects report
problems with aspects of everyday memory functioning) [29], visual analog scales (VAS), 10
cm lines on which subjects mark alcohol and other drug cravings on a 0 to 100 scale (e.g.,
[30]), Fatigue Severity Scale (FSS), 9-item scale to rate self-reported tiredness [31], Brief Pain
Inventory (BPI) [32], and Pittsburgh Sleep Quality Index (PSQI), a 10-item scale to investigate
several aspects of sleep quality [33]. Interviews were conducted in clinical space at the VA
Portland Health Care System (VAPORHCS) by three trained research associates under the
direction of neuropsychologist Marilyn Huckans, PhD. Diagnoses and interpretation of
responses to structured interviews were discussed at weekly meetings with Dr. Huckans, but
no formal inter-rater reliability measures were calculated. Blood was drawn from non-fasting
participants at rest by one-time venipuncture in clinic at the VAPORHCS. Samples were col-
lected in cell preparation tubes (BD Vacutainer Systems, Franklin Lakes, NJ, USA) containing
1 ml of 0.1M sodium citrate solution. Peripheral blood mononuclear cells (PBMCs) were iso-
lated per standard operating procedures. PBMCs were washed twice in RPMI/5% FBS and
then counted before freezing and storage in liquid nitrogen.
DNA extraction, PCR amplification, and TAAR1 sequencing
DNA was extracted using Puregene kits (Qiagen Inc., Germantown, MD, USA). PCR was per-
formed on an Applied Biosystems (ABI) 9600 thermocycler using TAAR1 specific primers
(Forward 5’ CCTGATTATGGATTTGGGAAAA 3’ Reverse 5’ TCATAAAGGTCAGTACCCC
AGA 3’) using Amplitaq gold 360 (Applied Biosystems, Foster City, CA, USA). DNA
sequencing was performed using ABI BigDye v3.1 cycle sequencing reagents and analyzed on
an ABI 3130XL Genetic Analyzer. DNA extraction quality analysis of 12 samples found that
the 260/280 ratios were between 1.7 and 2.0 and all 260/230 ratios were greater than 1.5; the
yields ranged from 7–27 μg at a concentration between 37 and 127 ng/μl. The variation in
yield was due to differences in the initial cell numbers. Average yield was 19 μg and 92 ng/μl.
TAAR1 polymorphism analysis
The TAAR1 variants were detected by direct Sanger sequencing and analyzed by using
Sequencher 5.0 software (Gene Codes Corporation, Ann Arbor, MI, USA). Briefly, the
sequencing data were trimmed to remove the low quality area. The variants were identified by
comparative sequence alignments among the samples to the human TAAR1 reference
sequence (NCBI reference sequence NC_000006.12: c132646026-132644898/NM_138327.2).
The potential heterozygotes were analyzed by the ratio of primary and secondary peaks and
manually validated. The candidate variants from the sample sequence were determined by
comparison with the established NCBI dbSNP database and Ensembl SNP database.
Trace amine-associated receptor gene polymorphism and drug craving
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In vitro expression and function of CV and wild type (WT) TAAR1
receptors
Chinese Hamster Ovary (CHO-K1) cells in culture were transfected with 2.5 μg/10 cm dish of
either WT or CV venus-tagged cDNA. Protein expression and fluorescence were measured by
a modification of our previously described methods [15]. EC50 values for the effects of β-phe-
nethylamine (β-PEA) on cAMP production were also determined according to Shi et al.
(2016). Secondary WT and CV mRNA structure was determined using RNAstructure tool
software (http://rna.urmc.rochester.edu/RNAstructureWeb/).
Statistical analysis
For in vitro experiments, differences in light intensity between WT and CV TAAR1-trans-
fected cells were analyzed by Student’s t-test. Dose-response curves for cAMP accumulation
were analyzed by nonlinear regression using GraphPad Prism (San Diego, CA, USA).
Between-group differences were assessed by one-way analysis of variance (ANOVA) or two-
way ANOVAs of genotype by β-PEA concentration, followed with Tukey’s multiple compari-
son test using GraphPad Prism software (San Diego, CA, USA). P-values < 0.05 were consid-
ered significant. To evaluate the relationship between TAAR1 genotype and neuropsychiatric
function, principal component analysis (PCA) was applied to the correlation matrix of pre-
specified neuropsychiatric characteristics of interest. Components were retained until at least
80% of the overall variance was accumulated. Those retained were rotated (orthogonal Vari-
max) to clarify the structure and limit neuropsychiatric characteristics from loading on multi-
ple components simultaneously. PC scores were computed and correlated against individual
neuropsychiatric characteristics to facilitate interpretation and identify dominant characteris-
tics within each PC. Scores were then used as the response of interest in separate generalized
linear models (GLM) with study group, TAAR1 genotype, and the interaction between these
factors as predictors of primary interest, while adjusting for key demographic variables found
also to be associated with the response. Exploratory plots revealed skewness in PC scores and
increasing standard deviation proportional to the mean, so the GLM utilized a gamma distri-
bution (with log link) after adding a small amount to all values sufficient to ensure all values
were positive (shifted +1.4). Robust standard errors were used for estimation and testing to
guard against potential mis-specification of the underlying distribution.
Results
In vitro expression and function of CV and WT TAAR1 receptors
There was greater TAAR1 protein expression over time in the cells transfected with cDNA for
the CV compared to WT receptor (Fig 1A, 1B and 1C). Note that at all post transfection time
points, the CV receptor was expressed at higher levels than the WT receptor, indicating that
this was not a transient kinetic phenomenon. Protein values and cell number were the same
across the constructs. Production of cAMP was higher in the CV- compared to WT-trans-
fected cells in response to β-PEA, but EC50 values did not differ (230 nM vs 237 nM for WT
and CV, respectively, Fig 1D and 1E). However, there was a significant increase in the maxi-
mal cAMP response to agonist stimulation in the cells expressing the CV, compared to the
cells expressing the WT receptor (Fig 1E). Determination of mRNA structure revealed that the
A! T substitution in the valine codon occurred near the base of a hairpin loop, but the pre-
dicted secondary structures were identical.
Trace amine-associated receptor gene polymorphism and drug craving
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Demographic and clinical characteristics
Demographic and clinical characteristics of study participants are summarized in Table 1. The
reported allelic frequency of the TAAR1 synonymous V288V SNP in the general population is
22% [34] and was 29% (95% CI: 23% - 36%) in our sample. The distribution of V288V geno-
types did not statistically differ among study groups (Table 1).
TAAR1 V288V genotype and neuropsychiatric symptoms
Common risk factors can contribute to both substance use disorders and the adverse effects on
mental health. We sought to determine whether the TAAR1 V288V genotype was associated
Fig 1. The common variant, V288V has higher expression and function in transfected cells. Cells were transfected and processed as
described in the text, and fluorescence was measured at 4 hours (A), 24 hours (B), and 48 hours (C). Expression of V288V was higher at all
time points compared to expression of the reference sequence (WT) (t-test, � p< 0.005). D) β-phenthylamine (β-PEA)-stimulated cAMP
production indicated a higher maximal response but no change in EC50 values across genotypes. Two-way ANOVA detected a significant
genotype by β-PEA concentration interaction [F(12,41) = 5.882; p< 0.0001), � p< 0.005, comparing WT and V288V variant]. E) One-way
ANOVA, followed with Tukey’s multiple comparison test compared cAMP levels between groups (�p< 0.005, comparing WT and V288V
variant; + p< 0.005, comparing untransfected (Un) cells and cells expressing the TAAR1 variants.
https://doi.org/10.1371/journal.pone.0220270.g001
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PLOS ONE | https://doi.org/10.1371/journal.pone.0220270 October 10, 2019 6 / 15
with addiction-related symptoms, specifically, neuropsychiatric characteristics involving
depression, anxiety, pain, sleep, drug and alcohol craving, and cognitive function. Principal
component analysis resolved the 10 characteristics into four principal components (PC) that
combine characteristics into distinct patterns: PC1 (mood/cognition) was a combination of
depression, anxiety, memory, and fatigue; PC2 was dominated by pain; PC3 involved craving;
and PC4 was driven by sleep disturbances (Table 2).
Scores for each principal component were analyzed to determine whether differences asso-
ciated with TAAR1 genotype varied by study group (i.e., TAAR1 x group interaction). For PC3
(craving response), and controlling for age, years of education, ethnicity, and sex, there was a
significant [X2(4df) = 15.82, p = 0.003] interaction between TAAR1 and study group. Control
participants showed no difference in PC3 associated with TAAR1 (fold change = 0.99,
p = 0.94), while the adjusted mean craving response for individuals in the MA-ACT and
MA-REM groups, among those with at least one copy of the TAAR1 V288V SNP (TAAR1 pos-
itive group), was estimated to be, respectively, 1.55 (95% CI: 1.03–2.35; p = 0.036) and 1.77
(95% CI: 0.95–3.27; p = 0.071) times the adjusted mean response for those without the TAAR1
SNP (TAAR1 negative group). Participants in the POLY-REM group evidenced a similar, but
non-significant trend; the adjusted mean craving response for the TAAR1 positive group was
estimated to be 1.34 (95% CI: 0.90–2.01; p = 0.152) times the adjusted mean response for the
TAAR1 negative group. In the POLY-ACT group, the direction reversed, such that the
Table 1. Demographic and clinical characteristics of study participants with and without a history of dependence on methamphetamine and other substances.
TAAR1 V288V genotype
Characteristic Negative (n = 54) Positive (n = 52) p-value
Study group (n, %) 0.431
CTL 17 31.5 14 26.9
MA-ACT 8 14.8 5 9.6
MA-REM 11 20.4 8 15.4
POLY-ACT 3 5.6 8 15.4
POLY-REM 15 27.8 17 32.7
Age [yrs] (mean, sd) 37.6 10.4 38.6 12.3 0.644
Sex (n, %) 0.485
Male 35 64.8 37 71.2
Female 19 35.2 15 28.8
Ethnicity (n, %) 0.857
Other 9 16.7 8 15.4
White 45 83.3 44 84.6
Yrs of education (mean, sd) 12.5 1.5 12.4 1.5 0.374
BMI [kg/m^2] (mean, sd) 27.7 4.6 25.9 4.6 0.056
Prescription meds. (n, %) 0.629
No 35 64.8 36 69.2
Yes 19 35.2 16 30.8
Current medical cond. (n, %) 0.880
No 20 37.0 20 38.5
Yes 34 63.0 32 61.5
Current smoker (n, %) 0.395
No 14 26.9 18 34.6
Yes 38 73.1 34 65.4
Abbreviations: ACT, active; BMI, body mass index; CLT, control; MA, methamphetamine; POLY, polysubstance
https://doi.org/10.1371/journal.pone.0220270.t001
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adjusted mean response for the TAAR1 positive group was lower (fold change = 0.61) than the
mean response for TAAR1 negative group (95% CI: 0.41–0.91; p = 0.016); however, the
POLY-ACT group was limited to only three WT participants and two of these were outliers
(Studentized residuals > 4.5). Therefore, a secondary analysis was performed, omitting the
outliers and with the POLY-ACT and POLY-REM groups combined. In addition, as the
skewed distribution of the craving component resulted primarily from inclusion of the craving
values of the CTL group, the CTL groups were omitted from the model. This reanalysis, using
a general linear model with genotype and group as main effects and age, sex, ethnicity, and
education as covariates, found no interaction between TAAR1 and diagnostic group. When
reanalyzed omitting the interaction term, there were significant main effects of TAAR1
(p< 0.025) and group (p< 0.002). Thus, inclusion or exclusion of the outliers did not affect
the overall conclusions. The main effect of TAAR1 genotype had a Cohen’s d = 0.58, indicating
a moderate effect size in the multiple regression analysis (see S1 Statistical Supplement).
Further testing revealed that the TAAR1 genotype effects in the MA-ACT and MA-REM
groups (i.e., 1.55- and 1.77-fold increases) did not differ significantly [X2 (1df) = 0.11,
p = 0.75], implying a shared underlying effect on craving for those with MA dependence,
either active or in early remission. Having at least one copy of the TAAR1 V288V SNP was
associated with a 1.68 (95% CI: 1.14–2.47, p = 0.009) fold increase in the adjusted mean craving
response as characterized by PC3. This suggests participants with TAAR1 V288V SNP in the
MA-ACT and MA-REM groups reported higher aggregated levels of craving (for alcohol, MA,
and other substances) than participants without the TAAR1 V288V SNP (Fig 2).
Discussion
This is the first study to describe the effects of an expression-modifying polymorphism of the
TAAR1 gene on characteristics of humans with a MA use disorder. These important findings
provide evidential support for the role of TAAR1 genotype in the craving response. The CV
SNP resulted in increased functional TAAR1 protein production in cell culture although it is
Table 2. Pattern structure (loadings) of addiction-related symptoms identified through PCAa.
Symptom (measure) PC1 PC2 PC3 PC4
Depression (PHQ-9) 0.491 -0.058 0.048 -0.001
Anxiety (GAD-7) 0.470 -0.090 0.078 0.109
Memory (PRMQ) 0.425 0.025 0.018 -0.080
Fatigue (FSS) 0.402 0.127 -0.107 -0.032
Pain severity (BPI) 0.023 0.706 -0.029 -0.102
Pain interference (BPI) -0.030 0.685 0.029 0.110
Alcohol craving (VAS) -0.256 0.004 0.834 -0.031
MA craving (VAS) 0.229 -0.013 0.365 0.084
Other craving (VAS) 0.255 0.050 0.350 -0.460
Sleep disturbance (PSQI) 0.107 0.043 0.163 0.859
Variance 3.55 1.85 1.78 0.86
Var. (%) 36 18 18 9
Cum. % 36 54 72 80
aThe dominant neuropsychiatric symptoms are highlighted with gray background. Abbreviations: PCA, principal
component analysis; PHQ-9, Patient Health Questionnaire; GAD-7, Generalized Anxiety Disorder 7-item scale;
PRMQ, Prospective and Retrospective Memory Questionnaire; FSS, Fatigue Severity Scale; BPI, Brief Pain Inventory;
VAS, visual analogue scale; PSQI, Pittsburgh Sleep Quality Inventory
https://doi.org/10.1371/journal.pone.0220270.t002
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not known whether this effect occurs in vivo. While the V288V SNP is synonymous, such
changes can affect the binding sites for splicing regulatory proteins and have significant effects
on pre-mRNA splicing and translation efficiency [35, 36]. As TAAR1 has a single exon, the
increased protein production demonstrated in Fig 1 is likely due to increased translation.
TAAR1 genotype has substantial effects on responses to amphetamines. In preclinical stud-
ies, MA drinking lines of mice, bred for high or low voluntary MA intake, and TAAR1 knock-
out mice demonstrate a major impact of the Taar1 gene on several MA-related responses (e.g.,
MA consumption, MA-induced conditioned taste aversion and conditioned place preference,
and MA-induced hypothermia [37, 38]). A mouse model of TAAR1 over-expression reported
increased spontaneous dopaminergic neuron firing rate and extracellular DA but blunted
extracellular dopamine and hyper-locomotion response to acutely administered amphetamine
[39].
Although other simulants (e.g., cocaine and methylphenidate) and alcohol reliably increase
dopamine release in the striatum, amphetamines are unique substrates of the dopamine trans-
porter (DAT) that can interact with intracellular TAAR1 [40]. Acute amphetamine, via agon-
ism at the intracellular TAAR1 receptor, causes internalization of the DAT [41, 42] and a
glutamate transporter (excitatory amino acid transporter 3, EAAT3) [43]. Chronic MA expo-
sure causes long-term decreases in DAT in animals [44, 45] and humans [46, 47]. It is possible
that individuals with a history of MA use who are homozygous or heterozygous with the
V288V polymorphism (and presumptive TAAR1 overexpression) may have even lower DAT
numbers than WT individuals, greater dopamine persistence in the synapse in ventral
Fig 2. Illustrates the craving response (vertical axis), as found by PCA and separated according to study group
and TAAR1 status (horizontal axis). Individual values are shown as black (WT = no V288V polymorphism) or
gray (CV = homozygous or heterozygous for V288V polymorphism) circles, with median value indicated by
horizontal dash. For individuals with a history of methamphetamine (MA) dependence, the TAAR1 positive response
was ~1.68 times the negative response, indicating that participants with the TAAR1 V288V SNP reported higher levels
of craving (for alcohol, MA, and other addictive drugs) than participants without the TAAR1 V288V SNP.
Abbreviations: ACT, active; CV, common variant; POLY, polysubstance; REM, remission; WT, wild-type.
https://doi.org/10.1371/journal.pone.0220270.g002
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tegmental area and nucleus accumbens ventral striatum and thus greater craving due to the
influence of these regions on corticolimbic targets [48]).
Interestingly, the TAAR1 gene does not occur in genetic databases referencing addiction or
neuropsychiatric disorders associated with dopaminergic pathology. These include databases
generated from studies on: 1) subjective responses to amphetamines [49], 2) self-reported alco-
hol consumption [50], 3) cocaine dependence [51], 4) schizophrenia [17, 52], and 5) Parkin-
son’s disease [53]. A recent genome-wide association study (GWAS) that investigated alleles
that correlated with shared risk for alcohol (n = 521 participants), heroin (n = 1026 partici-
pants), and MA (n = 1749 participants) did not identify TAAR1 [54]. This report is important
as one of the only GWAS investigation of MA addiction, but the number of individuals with
MA use disorder is still rather small and may miss genes of small effect or those that are neces-
sary but not sufficient to confer risk. The lack of association with other substances of abuse is
not entirely surprising as MA is a substrate of the DAT and an agonist at the intracellular
TAAR1 receptor, while alcohol, cocaine, cannabinoids, and opioids are not transported into
the cell nor do they act at the receptor. We suggest that the CV exerts its influence in MA use
disorder after the individual becomes addicted to MA and does not confer risk for developing
addiction per se. Therefore, we do not find it surprising that the CV, which exerts its influence
through over expression of TAAR1, is only associated with the disorder after chronic exposure
to MA. The Hart et al. (2012) paper deserves separate mention, as that study investigated sub-
jective response to amphetamine in healthy volunteers and did not identify the CV as explain-
ing any of the variance in subjective experience. This accords with our hypothesis that the CV
exerts its behavioral effects (e.g., craving) only after addiction has developed in MA use disor-
der and may, therefore, not affect subjective response in those without a history of MA
exposure.
This study has some limitations. Current nicotine and caffeine users were not excluded.
Smoking, and to a lesser extent, caffeine use, is common in substance using populations and
exclusion of these subjects would have resulted in recruitment of an atypical sample. Smoking
was, however, distributed evenly between the V288V and WT subgroups and was thus unlikely
to have affected the conclusions. In addition, the sample size for this investigation is small for
genetic studies. Nevertheless, there was a statistically significant moderate effect (d = 0.58) of
genotype on craving demonstrated in the MA using groups. As this effect size is associated
with a power of about 0.5 for this number of subjects, it is not unlikely that the effect was
detected. Confirmation of the genotype effect with larger samples would increase confidence
in this finding. Also, as there were only two V288V homozygotes in the MA groups, if was not
possible to evaluate a possible gene dose effect.
Conclusions
This study is the first study to report on the effects of a polymorphism of the TAAR1 gene on
characteristics of humans with a MA use disorder, but it is not without limitations, including
the use of a cross-sectional study design which did not allow for definitive conclusions on cau-
sality and small group sample sizes that may have limited our statistical power to some extent.
More studies are necessary to address these limitations and to expand our understanding of
the effects of TAAR1 genotype on neuroadaptations that result from chronic MA. To the
extent that craving is associated with dopamine receptor stimulation [55], individuals with the
CV and a history of chronic use would experience greater dopamine persistence in the synapse
and thus greater craving. Elucidation of the mechanism of this effect is needed, as the TAAR1
is increasingly being described as a promising therapeutic target for neuropsychiatric disorders
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[13, 56, 57], and SNPs in TAAR1 could provide a tool for individualizing treatments to
improve early intervention strategies for the treatment of MA use disorder.
Supporting information
S1 Statistical Supplement. Calculation of effect size of TAAR1 genotype and post-hoc
power are summarized and discussed.
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